Abstract
C-peptide is part of the, which its amounts were equal to endogenous insulin secreted by pancreatic β cells. Carboplatin is one of the chemotherapy regimens that are widely used to treat gynecological malignancies. Carboplatin may cause the damage of β-islets of Langerhans, which may cause defects in insulin synthesis leading to secondary diabetes mellitus or other types of diabetes mellitus. The purpose of this study was to determine the differences in C-peptide, (which reflects endogenous insulin levels) levels in patients with gynecologic malignancy who underwent carboplatin chemotherapy. This study was a comparative observational study with a cross-sectional design. There was a total of 42 subjects who met the inclusion criteria. Subjects with gynecological malignancy post-carboplatin chemotherapy regimens had lower serum C-peptide levels in group II compared to group I. Serum C-peptide levels can further be used to monitor side effects of carboplatin and can be used as a test to diagnose the other types of diabetes mellitus especially before starting the fourth cycle
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
